Format

Send to

Choose Destination
Nature. 2019 Jul;571(7763):72-78. doi: 10.1038/s41586-019-1315-z. Epub 2019 Jun 19.

Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes.

Author information

1
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
2
Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, USA.
3
Department of Genetics, Harvard Medical School, Boston, MA, USA.
4
Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA, USA.
5
Rush University Medical Center, Chicago, IL, USA.
6
Department of Biochemistry, Stanford University, Stanford, CA, USA.
7
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
8
Saint Louis University School of Medicine, St Louis, MO, USA.
9
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
10
Regeneron Pharmaceuticals, Tarrytown, NY, USA.
11
Regulatory and Quality Solutions LLC, Braintree, MA, USA.
12
Boston University School of Medicine, Boston, MA, USA.
13
Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA.
14
Yale School of Medicine, New Haven, CT, USA.
15
Caribou Biosciences, Berkeley, CA, USA.
16
College of Information and Computer Sciences, University of Massachusetts Amherst, Amherst, MA, USA.
17
Department of Computer Science, Texas A&M University, College Station, TX, USA.
18
Broad Institute of MIT and Harvard, Cambridge, MA, USA. dhung@broadinstitute.org.
19
Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, USA. dhung@broadinstitute.org.
20
Department of Genetics, Harvard Medical School, Boston, MA, USA. dhung@broadinstitute.org.

Abstract

New antibiotics are needed to combat rising levels of resistance, with new Mycobacterium tuberculosis (Mtb) drugs having the highest priority. However, conventional whole-cell and biochemical antibiotic screens have failed. Here we develop a strategy termed PROSPECT (primary screening of strains to prioritize expanded chemistry and targets), in which we screen compounds against pools of strains depleted of essential bacterial targets. We engineered strains that target 474 essential Mtb genes and screened pools of 100-150 strains against activity-enriched and unbiased compound libraries, probing more than 8.5 million chemical-genetic interactions. Primary screens identified over tenfold more hits than screening wild-type Mtb alone, with chemical-genetic interactions providing immediate, direct target insights. We identified over 40 compounds that target DNA gyrase, the cell wall, tryptophan, folate biosynthesis and RNA polymerase, as well as inhibitors that target EfpA. Chemical optimization yielded EfpA inhibitors with potent wild-type activity, thus demonstrating the ability of PROSPECT to yield inhibitors against targets that would have eluded conventional drug discovery.

PMID:
31217586
DOI:
10.1038/s41586-019-1315-z

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center